Research programme: synthetic triacyl compounds - OM Pharma

Drug Profile

Research programme: synthetic triacyl compounds - OM Pharma

Alternative Names: OM-197-MP-AC - OM Pharma

Latest Information Update: 09 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OM Pharma
  • Developer Vifor Pharma
  • Class
  • Mechanism of Action Toll-like receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Hypersensitivity

Most Recent Events

  • 01 May 2014 Discontinued - Preclinical for Cancer in Switzerland (unspecified route)
  • 01 May 2014 Discontinued - Preclinical for Hypersensitivity in Switzerland (unspecified route)
  • 24 Feb 2011 Preclinical trials in Cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top